Pharsight

Drugs that contain Baricitinib

1. Olumiant patents expiration

OLUMIANT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8158616 ELI LILLY AND CO Azetidine and cyclobutane derivatives as JAK inhibitors
Jun, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420629 ELI LILLY AND CO Azetidine and cyclobutane derivatives as JAK inhibitors
Mar, 2029

(5 years from now)

US9737469 ELI LILLY AND CO Methods for treating hair loss disorders
Nov, 2031

(7 years from now)

US11806555 ELI LILLY AND CO Methods for treating hair loss disorders
Nov, 2031

(7 years from now)

US9089574 ELI LILLY AND CO Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
Nov, 2032

(8 years from now)

US11045474 ELI LILLY AND CO Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections
Nov, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) May 10, 2025

Market Authorisation Date: 31 May, 2018

Treatment: Treatment of rheumatoid arthritis; Treatment of adult patients with severe alopecia areata; Treatment of coronavirus disease 2019 (covid-19) in hospitalized adults requiring supplemental oxygen, non-i...

Dosage: TABLET;ORAL

How can I launch a generic of OLUMIANT before it's drug patent expiration?
More Information on Dosage

OLUMIANT family patents

Family Patents